[Possible cardiotoxicity induced by orally administered fluoropyrimidines]

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Fluoropyrimidines, including 5-fluorouracil (5-FU), Ptorafur, and UFT, are widely used chemotherapy agents.
• Cardiotoxicity is a known but not fully understood side effect of these drugs.
• The incidence and specific manifestations of cardiotoxicity in patients without pre-existing cardiac conditions warrant further investigation.

Observation:

• Four new cases of cardiotoxicity associated with 5-FU or oral fluoropyrimidines (Ptorafur, UFT) are reported.
• Patients generally had no history of heart disease, with one exception.
• Observed toxicities included myocardial ischemia and electrocardiogram (EKG) changes in three patients with measured cardiac enzymes.

Findings:

• The study presents additional evidence linking 5-FU and oral fluoropyrimidines to cardiotoxicity.
• Myocardial ischemia and EKG abnormalities are key indicators of this drug-induced toxicity.
• The findings underscore the importance of monitoring cardiac function during treatment with these agents.

Implications:

• Increased awareness among clinicians regarding the potential for cardiotoxicity from 5-FU and oral fluoropyrimidines, even in patients without prior heart disease.
• The need for vigilant cardiac monitoring and prompt management strategies for patients receiving these chemotherapeutics.
• Further research into the etiopathogenesis and predictive markers of fluoropyrimidine-induced cardiotoxicity is crucial for improving patient outcomes.